Editorial: Women in molecular and cellular oncology

Frontiers in Oncology

Oncology

Ana Paula Lepique¹  Shilpa S. Dhar²  Valeria Poli³  Petranel T. Ferrao⁴  Laura Rosanò⁵ 

[1] Department of Immunology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil;Department of Molecular & Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States;Department of Molecular Biotechnology and Health Sciences, University of Turin, Torino, Italy;Independent Researcher, Adelaide, SA, Australia;Precision Medicine, South Australian Health and Medical Research Institute, North Terrace, Adelaide, SA, Australia;Corpallium Pty Ltd, Adelaide, SA, Australia;Plena Vitae Therapies Pty Ltd, Adelaide, SA, Australia;Institute of Molecular Biology and Pathology, Consiglio Nazionale delle Ricerche (CNR), Rome, Italy;

关键词: gender equality;    STEMM;    cancer;    oncology clinical trials;    treatment cross-resistance;    female leadership;    diversity;   

DOI  :  10.3389/fonc.2023.1257780

 received in 2023-07-13, accepted in 2023-08-01,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Ferrao, Rosanò, Poli, Dhar and Lepique